Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
Journal: The Lancet. Oncology
Published: June 16, 2025
Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer.
Journal: Oncology and therapy
Published: June 08, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Journal: The New England journal of medicine
Published: June 02, 2025
Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.
Journal: The oncologist
Published: June 03, 2024
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Journal: American journal of hematology
Published: January 02, 2024
A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.
Journal: Frontiers in pediatrics
Published: March 09, 2023
Showing 1-7 of 7
Last Updated: 09/26/2026